Anticoagulation for Cerebral Venous Thrombosis with Subarachnoid Hemorrhage: A Case Report

Mohamed Osama Hegazi\textsuperscript{a}  Sherif Ahmed\textsuperscript{a}  Mohamed Gaber Sakr\textsuperscript{b}  Omar Ahmed Hassanien\textsuperscript{c}

Departments of \textsuperscript{a}Medicine, \textsuperscript{b}Casualty and \textsuperscript{c}Radiology, Al-Adan Hospital, Kuwait

\textbf{Case Report}

A 38-year-old woman presented with acute onset of severe diffuse headache with vomiting for the last 12 h. She was not pregnant or puerperal, nor on contraceptive pills, and did not have any past or family history of venous thrombosis. She was fully con-
Conscious, afebrile and her neck was rigid, but no focal neurological deficits could be elicited. Urgent brain CT showed evidence of CVT and SAH (fig. 1). Laboratory workup showed normal full blood count, normal renal, hepatic and coagulation profiles, and negative antiphospholipid antibodies. Tests for plasma fibrinogen, protein C, protein S, activated protein C resistance and antithrombin-III were normal. Checking for the prothrombin gene mutation (G20210A) was not carried out; however, this type of thrombophilia is extremely rare in individuals of Asian descent, like our patient [5]. Treatment with analgesia and mannitol was started, and the patient was closely observed. Brain magnetic resonance angiography with venography confirmed superior sagittal and right transverse sinus thromboses, and was negative for vascular malformations (fig. 2). AC with low-molecular-weight heparin (enoxaparin 1 mg/kg twice daily) was started 4 days after the onset of symptoms, and when repeated CT showed that SAH had regressed. The patient’s symptoms disappeared, and she had an uneventful course thereafter. Heparin was changed to warfarin, and she was asymptomatic over a 12-month follow-up period.

Discussion

CVT is an uncommon serious neurological emergency that is being increasingly diagnosed due to better clinical awareness and improved imaging techniques. Prothrombotic risk factors, infections and Behcet’s disease are among the most frequently identified causes [2]. Presenting symptoms and signs include headache, epilepsy, focal neurological deficits and impairment of consciousness [2]. The priority of treatment in the acute stage should be to stabilize the patient’s condition and to prevent or reverse cerebral herniation [2].

Although there is no substantial evidence-based consensus that AC is beneficial in CVT, most neurologists currently start treatment with heparin as soon as the diagnosis is confirmed, even in the presence of hemorrhagic complications [2]. Heparin treatment has been shown to be beneficial rather than hazardous when CVT is associated with ICH [1, 3, 4]. Of 43 patients with CVT and ICH, Einhäupl et al. [1] reported a mortality of 15% in heparin-treated patients compared to 69% that in those who did not receive heparin. Of 29 patients with ICH and CVT who were treated with low-molecular-weight heparin, de Bruijn and Stam [3] reported 6 deaths, but none of them could be attributed to new or enlarged cerebral hemorrhage. In our case, AC therapy was associated with a favorable outcome, bearing in mind it was started 4 days after the onset of symptoms and after confirming that SAH had regressed. An important point is the safety of immediate AC with cases of SAH and CVT upon presentation. This point needs further clarification as in most of the reported cases of CVT with ICH, heparin treatment was delayed [1, 3, 6, 7]. Wingerchuk et al. [6] stated

Fig. 1. Brain CT showing SAH and transverse sinus thrombosis (T).

Fig. 2. Brain magnetic resonance angiography with venography showing superior sagittal sinus thrombosis (between arrows).
that AC was safely initiated within several days in clinically stable patients with non-temporal-lobe hemorrhagic infarcts of unchanged volume, and highlighted that the location and unchanged volume on serial CT may be important factors influencing the safety of AC therapy in patients with CVT and hemorrhagic infarcts. Oppenheim et al. [7] suggested performing magnetic resonance angiography, or preferably digital subtraction angiography, to rule out intracranial aneurysm before AC in cases of CVT with SAH. In the study by Einhäupl et al. [1], mean delay between the onset of symptoms and heparin treatment was 33 days; in the study of Bruijn and Stam [3], this was 10.6 days. No studies were found to evaluate the time interval when enlargement of venous intracerebral hemorrhages is more likely to occur; however, in general, active bleeding into the brain is usually confined to the first 6 h following ICH, with 10–15% of patients showing hematoma enlargement between 6 and 24 h from the onset of spontaneous ICH [8].

Conclusion

AC treatment for cases of CVT with hemorrhagic complications was not associated with adverse outcome. However, if ICH is present, immediate AC for CVT at presentation and within 24 h from onset of symptoms cannot be safely recommended, as in almost all previous reports there was a delay in the onset of AC ranging between 4 and 33 days. Although there is no known definite waiting period, repeating CT after at least 1 day from onset of symptoms to confirm that ICH is regressing or at least not progressing may be advisable before starting AC. It may also be prudent to perform magnetic resonance angiography or digital subtraction angiography before AC in cases of CVT with SAH to rule out a coincident intracranial aneurysm.

References